Attorney Docket No. 27373/34978A

# TRADEMARK OFFICE IN THE UNITED STATESTECHER

pplicants: Lindquist et al. I hereby certify that this paper is being deposited with the United States Postal Serial No.: 09/591,632 Service as first class mail, postage prepaid, envelope addressed an Filed: June 9,2000 Commissioner for Patents, Washington, DC 20231 on this date: For: Recombinant Prion-like Genes February 8, 2001 and Proteins and Materials and Methods Comprising Same Group Art Unit: 1644 David A. Gass, Esq. Reg. No. 38,153 Examiner: To be assigned. Attorney for Applicants

## REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

Sir:

Attached hereto is a copy of a corrected filing receipt issued by the Patent Office. The applicants respectfully request issuance of a new filing receipt that identifies only six inventors and removing the duplicate name of "JiYan Ma, Chicago, IL". (Jiyan Ma's name should appear only once.)

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN, **MURRAY & BORUN** 

By

David A. Gass

Registration No. 38,153 Attorneys for Applicants

6300 Sears Tower

233 South Wacker Drive Chicago, Illinois 60606-6402

(312) 474-6300

February 8, 2001

# RECEIVED

MAY 2 2 2001

UNITED STATES

www.uspta.gov

FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS FILING DATE **GRP ART UNIT** APPLICATION NUMBER 942 1644

United States Patent and Trademark Office

09/591.632

06/09/2000

27373/34978A

38

IND CLAIMS

12

Marshall O'Toole Gerstein Murray & Borun 800 Sears Tower 233 South Wacker Drive Chicago, IL 60606-6402

RECEIVED FEB 05 2001

MARSHALL O'TOOLE

CORRECTED FILING RECEIPT 

Date Mailed: 02/01/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Susan Lindquist, Chicago, IL; Liming Li, Chicago, IL; Jivan Ma, Chicago, IL: Jia-Jia Liu, Chicago, IL; Neal Sondheimer, Chicago, IL; Thomas Scheibel, Chicago, IL; <del>JiYan Ma; Ohicago; IL+</del> Dremove7

# **Continuing Data as Claimed by Applicant**

THIS APPLN CLAIMS BENEFIT OF 60/138,833 06/09/1999

**Foreign Applications** 

If Required, Foreign Filing License Granted 08/24/2000



**SMALL ENTITY \*\*** 

Title

Recombinant prion-like genes and proteins and materials and methods comprising same

Preliminary Class

Data entry by : MEREDITH, WANDA

Team : OIPE

Date: 02/01/2001

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

## **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a scense may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 7 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

# PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231